Signal Medical Lands Warning Over Unapproved Hip Implants
The FDA slapped Signal Medical with a warning letter for marketing a hip implant system that had never been approved.
During a July 31 to Aug. 11, 2014, inspection of the firm’s Marysville, Mich., facility, the investigators from the Detroit district office found that MicroSeal Total Hip Acetabular System was adulterated because Signal didn’t have an active PMA or other marketing clearance on some system components.
Specifically, the hip system includes a hood feature integrated with two separate liner models that were never cleared. In addition, the company sells two other liner sizes beyond the three available when the product was cleared for marketing.
The products are misbranded because Signal changed the device shell and liner without getting FDA approval, the warning letter says. The company responded to the Form 483, but did not address the issue of misbranding.
Whether you need to help your company convince the FDA to accept a predicate device in a simple 510(k) filing or you’re responsible for implementing UDI across a family of high-risk implantable devices, there’s one thing all regulatory professionals need: the most up-to-date, latest FDA regulations available. That’s why the Guide to FDA Medical Device Regulations - 2015 Edition is an FDAnews best-seller.